Compare FSI & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSI | IMA |
|---|---|---|
| Founded | 1991 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.3M | 65.4M |
| IPO Year | 1999 | N/A |
| Metric | FSI | IMA |
|---|---|---|
| Price | $5.53 | $7.00 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 56.9K | 36.8K |
| Earning Date | 11-14-2025 | 03-18-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $38,563,427.00 | $800,000.00 |
| Revenue This Year | $7.49 | N/A |
| Revenue Next Year | $53.12 | N/A |
| P/E Ratio | $39.44 | ★ N/A |
| Revenue Growth | ★ 0.18 | N/A |
| 52 Week Low | $3.46 | $5.70 |
| 52 Week High | $11.48 | $18.00 |
| Indicator | FSI | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 32.32 | 50.67 |
| Support Level | $5.65 | $6.92 |
| Resistance Level | $6.02 | $7.60 |
| Average True Range (ATR) | 0.29 | 0.45 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 6.43 | 62.26 |
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The firm also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.